Preventing hospitalizations for respiratory syncytial virus infection

Paediatrics and Child Health (Canada)

Volumn 20, Issue 6, 2015, Pages 321-326

  Robinson, Joan L ^a   Saux, Nicole Le ^a  

^a NONE

Author keywords

At risk infants; Chronic lung disease; Congenital heart disease; Palivizumab; Prematurity; Prophylaxis; RSV

Indexed keywords

PALIVIZUMAB;

CANADA; CHILD HOSPITALIZATION; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INDIGENOUS PEOPLE; INFECTION PREVENTION; LUNG DISEASE; NONHUMAN; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; UPPER RESPIRATORY TRACT OBSTRUCTION;

EID: 84941628695     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/20.6.321     Document Type: Review

References (64)

1. Tan B; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Palivizumab and respiratory syncytial virus globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4(7):474-80.
2. Langley JM; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8(10):631-3.
3. Sampson L; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14(8):521-6.
4. Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing respiratory syncytial virus infections. Paediatr Child Health 2011;16(8):487-8.
5. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2010;(1):CD006207.
6. Mitchell I, Paes BA, Li A, Lanctôt KL; the CARESS investigators. CARESS: The Canadian Registry of Palivizumab. Pediatr Infect Dis J 2011;30(8):651-5.
7. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit 2002;24(3):444-5.
8. Paes BA, Craig C, Pigott W, Latchman A. Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data. Pediatr Infect Dis J 2013;32(9):e360-4.
9. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-7.
10. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant heart disease. J Pediatr 2003;143(4):532-40.
11. Robinson KA, Odelola OA, Saldanha I. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2014; (5):CD007743.
12. Homaira N, Rawlinson W, Snelling TL, Jaffe A. Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: A real-world perspective. Int J Pediatr 2014;2014:571609.
13. Chang SG, Park MS, Yu JE. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. J Korean Med Sci 2010;25(2):251-6.
14. Henckel E, Luthander J, Berggren E, et al. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J 2004;23(1):27-31.
15. Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int 2006;48(4):362-8.
16. Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA. Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays. Pediatr Infect Dis J 2013;32(10):1144-6.
17. Smart KA, Lanctôt KL, Paes BA. The cost effectiveness of palivizumab: A systematic review of the evidence. J Med Econ 2010;13(3):453-63.
18. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;165(6):498-505.
19. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. New Engl J Med 2013;368(19):1791-9.
20. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lactôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12(4):361-70.
21. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89(10):961-5
22. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects-hospitalizations and costs. Acta Paediatr 2006;95(4):404-6.
23. Wang EE, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics 1997;99(3):E9.
24. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137(6):865-70.
25. Simões EA, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133(4): 492-9.
26. Eriksson M, Bennet R, Rotzén-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91(5):593-8.
27. Medrano López C, García-Guereta L; CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: The Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J 2010;29(12):1077-82.
28. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants: Implications for use of RSV immune globulin. Arch Dis Child 2000;83(2):122-7.
29. Berner R, Schwoerer F, Schumacher RF, Meder M, Forster J. Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr 2001;160(9):541-7.
30. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22(9):823-7.
31. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99(1):93-9.
32. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85(6):463-8.
33. Rietveld E, Vergouwe Y, Steyerberg EW, et al. Hospitalization for respiratory syncytial virus infection in young children: Development of a clinical prediction rule. Pediatr Infect Dis J 2006;25(3):201-7.
34. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009;25(7):1585-91.
35. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134(2): 415-20.
36. Park HW, Lee BS, Kim AR, et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J 2012;31(8):e99-104.
37. Grimaldi M, Gouyon B, Sagot P, et al. Palivizumab efficacy in preterm infants with gestational age or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol 2007;42(3): 189-92.
38. Resch B, Pasnocht A, Gusenleitner W, Mller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 2005;50(5):397-403.
39. Lacaze-Masmonteil T, Truffert P, Pinquier D, et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child 2004;89(6):562-7.
40. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788-93.
41. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics 2004;114(6):1612-9.
42. Ambrose CS, Anderson EJ, Simões EA, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J 2014;33(6):576-82.
43. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006;41(12):1167-74.
44. Banerji A, Bell A, Mills EL, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164(13): 1847-50.
45. Banerji A, Panzov V, Robinson J, Young M, Ng K, Mamdani M. The cost of lower respiratory tract infections hospital admissions in the Canadian Arctic. Int J Circumpolar Health 2013;72.
46. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health 2007;12(7):563-6.
47. Banerji A, Young M, Bisson D et coll. Is an ounce of palivizumab worth a pound of cure? [résumé] Can J Infect Dis Med Microbiol 2010;21:189.
48. Banerji A, Greenberg D, White LF, et al. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: A case-control study. Pediatr Infect Dis J 2009;28(8):697-701.
49. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: The importance of lymphopenia and young age. Pediatrics 2008;121(2):235-43.
50. Robinson JL, Grenier D, MacLusky I, Allen UD. Respiratory syncytial virus infections in paediatric transplant recipients: A Canadian Paediatric Surveillance Program study. Pediatr Transplant 2015;19(6):659-62.
51. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008;43(2):169-74.
52. Winterstein AG, Eworuke E, Xu D, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol 2013;48(9):874-84.
53. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birth-cohort study. Pediatrics 2007;120(4):e1076-81.
54. Bloemers BL, van Furth AM, Weijerman ME, et al. High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J 2010;29(1):39-42.
55. Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 2010;29(7):672-3.
56. Paes B, Mitchell I, Yi H, Li A, Lanctôt KL; CARESS Investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J 2014;33(2):e29-33.
57. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176(5):1215-24.
58. Subramanian KN, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia: MEDI-493 Study Group. Pediatr Infect Dis J 1998;17(2):110-15.
59. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit 2002;24:444-5.
60. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus antibody, in adults and children. Antimicrob Agents Chemother 2012;56(9):4927-36.
61. Solimano A, Kwan E. Revisiting palivizumab (PVZ) dosing recommendations based on published pharmacokinetics data. [Abstract 4350.8]. Pediatric Academic Societies Meeting. Boston, April 28 to May 1, 2012.
62. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr 2015;169(4):341-8.
63. Solimano A, Eastman P, Butler A, Taylor R, MacRae S. Three seasonal palivizumab doses over four seasons is perfectly adequate RSV prophylaxis for moderate risk infants. [Abstract 4159.437]. Pediatric Academic Societies Meeting. San Diego, April 25 to 28, 2015.
64. Solimano A, Eastman P, Butler A, et al. The approval of four seasonal palivizumab doses provides cost-effective protection in infants at high risk of RSV admission during the five-month British Columbia season-A multi-season analysis. [Abstract 4159.436]. Pediatric Academic Societies Meeting. San Diego, April 25 to 26, 2015.